An electronic nose discriminates exhaled breath of patients with untreated pulmonary sarcoidosis from controls
Dragonieri S, Brinkman P, Mouw E, Zwinderman AH, Carratú P, Resta O, Sterk PJ, Jonkers RE
Because making the diagnosis sarcoidosis can be complex, it is important to improve the diagnostic process. In this article we describe an 'electronic nose' to check heter or not it can potentials identify sarcoidosis patients. They did this by comparing the exhaled air of untreated sarcoidosis patients with healthy controls. They did found that the exhaled air was different.
How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?: Making the right clinical decisions for rare diseases with the right tools.
Anne Musters en Sander W. Tas
This article is an editorial in the scientific journal 'Rheumatology'. Evaluating the effects and safety of modern treatment agents which treat rare diseases can be complex, because it can be difficult to properly investigate them in a qualitative clinical trial due to the low number of patients with this disease. Therefore, it is important to adequately describe the effects of these treatments. This article suggests the five domains of the 'Rare IMID Disease Activity Score' (RIDAS).